SECTION 04 / COMPARATOR · APPROVED ANALOG
CJC-1295 vs tesamorelin: the approved-analog comparison in the research literature
Two GHRH analogs, two very different evidence tiers. Tesamorelin is the closest approved benchmark — not an equivalent.
Why tesamorelin is the benchmark
CJC-1295 vs tesamorelin is a comparison of the same drug class at opposite ends of the evidence scale. Both are GHRH analogs that stimulate the GH/IGF-1 axis. Only one is approved. Tesamorelin reached Phase 3 randomized controlled trials and regulatory approval for HIV-associated lipodystrophy; CJC-1295 reached early human pharmacokinetics and its long-acting program was discontinued [1].
That asymmetry is the whole point of putting them side by side. Tesamorelin shows what GHRH-axis stimulation can achieve when it is carried through controlled trials. CJC-1295 shares the mechanism but not the clinical evidence base. The benchmark is informative precisely because it is the ceiling the research chemical has not been tested against.
The two also differ by design, not just by evidence. Tesamorelin is a stabilized GHRH analog without the albumin-conjugation chemistry that gives CJC-1295 DAC its multi-day half-life; it is dosed once daily at 2 mg subcutaneously in its approved use [8], while CJC-1295's defining pharmacokinetic feature is the days-long residence of the DAC variant [1]. Reading them together therefore separates two things that get tangled in popular accounts: what an approved GHRH analog has been shown to do clinically, and what the long-acting chemistry of CJC-1295 does to a dose's duration.
What the tesamorelin trials measured
The tesamorelin evidence is clinical and randomized. In a Phase 3 program, tesamorelin (2 mg subcutaneously daily) selectively reduced visceral fat in HIV-associated lipodystrophy — the data that supported its approval [8]. A randomized clinical trial in HIV-infected patients with abdominal fat accumulation reported reduced visceral adipose tissue and liver fat versus placebo [7], and a separate randomized trial confirmed effects on visceral adiposity and metabolic endpoints [appended to the analog's evidence base] [14].
The evidence base is still being extended: a 2026 analysis reported body-composition, hepatic-fat, metabolic and safety outcomes of tesamorelin, the approved-analog data that serves as the closest benchmark for CJC-1295 [15]. None of these trials studied CJC-1295. They map what an approved GHRH analog has been shown to do, in a defined patient population, under trial conditions.
How does CJC-1295 compare to tesamorelin, the FDA-approved GHRH analog?
Tesamorelin is an FDA-approved GHRH analog with Phase 3 RCT data showing reduced visceral and hepatic fat in HIV-associated lipodystrophy [7][8]. CJC-1295 is an unapproved research chemical whose human evidence is limited to early pharmacokinetic studies [1]; tesamorelin is the closest approved benchmark, not an equivalent.
Where CJC-1295's evidence actually stops
CJC-1295's human record is the early-phase pharmacokinetic studies: dose-dependent GH and IGF-1 elevation over days, a 5.8-8.1-day half-life, preserved pulsatility [1][3]. There are no large efficacy trials, no long-term safety trials, and no approved indication anywhere. A ConjuChem Phase 2 trial in HIV-associated visceral obesity was discontinued and the DAC program did not advance [1].
Read together, the two analogs make the evidence tiers legible. Tesamorelin: Phase 3 RCT data, approved. CJC-1295: early-PK only, unapproved, WADA-prohibited. The mechanism is shared; the proof is not. The comparison page exists to keep that distinction honest, not to imply CJC-1295 inherits tesamorelin's clinical record.
What the comparison does and does not license
A shared mechanism is a real thing, and it is worth stating plainly: both compounds activate the GHRH receptor and raise GH and IGF-1 [2][7]. That is why tesamorelin is the right benchmark rather than some unrelated drug. But mechanism is the floor of an argument, not the ceiling. Two analogs can engage the same receptor and differ in potency, duration, safety profile, dosing and tolerability — and tesamorelin's body-composition results were established in a defined patient population, HIV-associated lipodystrophy, under controlled trial conditions [7][8].
So the comparison licenses one inference and forbids another. It licenses the statement that GHRH-axis stimulation, carried through Phase 3 trials, has demonstrated selective visceral-fat reduction in a specific indication [8]. It forbids the leap that CJC-1295 therefore does the same thing in healthy adults — because that has not been tested, and a 2026 outcomes analysis of tesamorelin continues to build the approved analog's evidence base, not CJC-1295's [15].
The honest framing, then, is asymmetry held in view. Tesamorelin tells you what is possible for the class when the trials are run. CJC-1295 tells you what was measured before its program stopped. Putting them on one board is how a reader sees both at once without mistaking the second for the first.
Comparison questions readers ask
Are peptides safer than TRT?
The two act on different axes — testosterone-replacement therapy supplies androgen directly, while CJC-1295 stimulates the GH/IGF-1 axis. There is no head-to-head safety trial; CJC-1295 itself has only early-phase human pharmacokinetic data [1], so "safer" is not established in the literature.
How do anabolic steroids compare to peptides like CJC-1295 and ipamorelin for muscle building and health risks over 50?
Anabolic steroids act on the androgen receptor; CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) stimulate endogenous GH and IGF-1 [2][10]. The published CJC-1295 evidence in adults is limited to short-term pharmacokinetic studies [1], so comparative muscle-building efficacy and long-term risk — at any age, including over 50 — are not characterized in controlled trials.
Which is better, MK-677 or CJC-1295 / ipamorelin?
MK-677 (ibutamoren) is an orally active ghrelin-receptor secretagogue; CJC-1295 is an injectable GHRH analog often paired with the GHRP ipamorelin [10]. They engage different receptors and no controlled head-to-head exists, so "better" depends on undefined endpoints rather than trial data [1].